Real-world characteristics of elderly patients with overactive bladder in the United States

References

• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37-49
   PubMed Web of Science ®Google Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36
   PubMed Web of Science ®Google Scholar
• Cisternas MG, Foreman AJ, Marshall TS, et al. Estimating the prevalence and economic burden of overactive bladder among Medicare beneficiaries prior to Medicare Part D coverage. Curr Med Res Opin 2009;25:911-19
   PubMed Web of Science ®Google Scholar
• Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000;6(11 Suppl):S574-S9
   PubMed Web of Science ®Google Scholar
• Jackson S. The patient with an overactive bladder – symptoms and quality-of-life issues. Urology 1997;50(6A Suppl):18-22
   PubMed Web of Science ®Google Scholar
• Chapple C, DuBeau C, Ebinger U, et al. Darifenacin treatment of patients ≥65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin 2007;23:2347-58
   PubMed Web of Science ®Google Scholar
• Dorschner W, Stolzenburg JU, Griebenow R, et al. Efficacy and cardiac safety of propiverine in elderly patients: a double-blind, placebo-controlled clinical study. Eur Urol 2000;37:702-8
   PubMed Web of Science ®Google Scholar
• Dubeau CE, Kraus SR, Griebling TL, et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. J Urol 2014;191:395-404
   PubMed Web of Science ®Google Scholar
• Foote J, Glavind K, Kralidis G, Wyndaele JJ. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol 2005;48:471-7
   PubMed Web of Science ®Google Scholar
• Hill S, Elhilali M, Millard RJ, et al. Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study. Curr Med Res Opin 2007;23:2697-704
   PubMed Web of Science ®Google Scholar
• Kosilov KV, Loparev SA, Ivanovskaya MA, Kosilova LV. Comparative effectiveness of combined low- and standard-dose trospium and solifenacin for moderate overactive bladder symptoms in elderly men and women. Urol Int 2014;93:470-3
   PubMed Web of Science ®Google Scholar
• Malone-Lee J, Shaffu B, Anand C, Powell C. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol 2001;165:1452-6
   PubMed Web of Science ®Google Scholar
• Minassian VA, Ross S, Sumabat O, et al. Randomized trial of oxybutynin extended versus immediate release for women aged 65 and older with overactive bladder: lessons learned from conducting a trial. J Obstet Gynaecol Can 2007;29:726-32
   PubMedGoogle Scholar
• Wagg A, Khullar V, Marschall-Kehrel D, et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. J Am Geriatr Soc 2013;61:185-93
   PubMed Web of Science ®Google Scholar
• Zaitsu M, Mikami K, Ishida N, Takeuchi T. Comparative evaluation of the safety and efficacy of long-term use of imidafenacin and solifenacin in patients with overactive bladder: a prospective, open, randomized, parallel-group trial (the LIST Study). Adv Urol 2011; https://www.hindawi.com/journals/au/2011/854697/
   Google Scholar
• Coyne KS, Sexton CC, Vats V, et al. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology 2011;77:1081-7
   PubMed Web of Science ®Google Scholar
• Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963;185:914-19
   PubMed Web of Science ®Google Scholar
• Rosow I, Breslau N. A Guttman health scale for the aged. J Gerontol 1966;21:556-9
   PubMedGoogle Scholar
• Wolinsky FD, Stump TE, Callahan CM, Johnson RJ. Consistency and change in functional status among older adults over time. J Aging Health 1996;8:155-82
   PubMed Web of Science ®Google Scholar
• Ivanova JI, Mytelka DS, Duh MS, et al. Evaluating the utility of existing patient-reported outcome scales in novel patient populations with pancreatic cancer, lung cancer, and myeloproliferative neoplasms using medicare current beneficiary survey data. Patient 2013;6:189-200
   PubMedGoogle Scholar
• Nagi SZ. An epidemiology of disability among adults in the United States. Milbank Mem Fund Q Health Soc 1976;54:439-67
   PubMedGoogle Scholar
• Saliba D, Elliott M, Rubenstein LZ, et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 2001;49:1691-9
   PubMed Web of Science ®Google Scholar
• International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Medical Dictionary for Regulatory Activities (MedDRA) Hierarchy. Available at: http://www.meddra.org/how-to-use/basics/hierarchy [Last accessed 2 March 2016]
   Google Scholar
• Charlson ME, Charlson RE, Peterson JC, et al. The Charlson Comorbidity Index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol 2008;61:1234-40
   PubMed Web of Science ®Google Scholar
• D’Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson Comorbidity Index with administrative data bases. J Clin Epidemiol 1996;49:1429-33
   PubMed Web of Science ®Google Scholar
• Cooney D, Pascuzzi K. Polypharmacy in the elderly: focus on drug interactions and adherence in hypertension. Clin Geriatr Med 2009;25:221-33
   PubMed Web of Science ®Google Scholar
• Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf 2014;13:57-65
   PubMed Web of Science ®Google Scholar
• Oelke M, Becher K, Castro-Diaz D, et al. Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age Ageing 2015;44:745-55
   PubMed Web of Science ®Google Scholar
• Sexton CC, Coyne KS, Thompson C, et al. Prevalence and effect on health-related quality of life of overactive bladder in older americans: results from the epidemiology of lower urinary tract symptoms study. J Am Geriatr Soc 2011;59:1465-70
   PubMed Web of Science ®Google Scholar